OBR daily eNewsOBR greenOBR IntelOBR FinancePipeline Online™OBR RadarEventsBlogAdvertise

 

Today's Featured Oncology Headlines Subscribe»

FDA Approves Inlyta to Treat Patients With a Type of Advanced Kidney Cancer

(FDA) Jan 27, 2012 - The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
read press release »

Gene Test May Aid Early-Stage Lung Cancer Patients

(San Francisco Chronicle) Jan 27, 2012 - In a finding that could improve the survival odds for early-stage lung cancer patients, UCSF researchers determined a new molecular test can predict more accurately than current diagnostic methods which tumors are more likely to be aggressive and turn deadly.
read article »

Infinity Stops Cancer Drug Trial, Shares Dive

(Reuters) Jan 27, 2012 - Infinity Pharmaceuticals pulled the plug on a mid-stage trial of its experimental pancreatic cancer drug as it failed to show benefit over a placebo, wiping off over 41 percent of its market value.
read article »

Cancer Screenings Remain Low for Minorities and the Uninsured, CDC Report Says

(Forbes) Jan 26, 2012 - A first-of-its kind federal study that looked at cancer screening rates in the U.S. has found that the percentage of Americans tested for three major types of cancer is inadequate. Asians, Hispanics, and the uninsured had particularly lower chances of being screened, the report by the Centers for Disease Control and Prevention and the National Cancer Institute said.
read article »

 

View ALL News »

		Our free daily oncology focused e-news service. Subscribe»  |  Search Archives»

---

Oncology Business Review January Issue

OBR green is our industry trade journal with carefully developed, exclusive oncology industry content.

More Content, More Timely, Less Trees.
Register for OBR green today.

Table of Contents

New Frontiers and Novel Mechanisms of Action in Hematologic Malignancies

At the 2011 American Society of Hematology (ASH) conference, a plethora of clinical data for new products in development for hematologic malignancies was presented. Focusing on the data from agents with novel mechanisms of action allows for an interesting look at the impact these agents may have on the competitive landscape.

Shining a Light: How the Sunshine Provision May Impact Promotion

Part of the Affordable Care Act, the Sunshine Act requires pharmaceutical and device manufacturers to provide a database to Health and Human Services outlining transfers of value to physicians, including lunches and pens! The searchable website, estimated to be available in September ’13, changes everything. As a result manufacturers are likely to change their promotional strategy, and physicians may be reconsidering their collaboration with industry. The Campbell Alliance explains the Act and its potential consequences.

Consumerism in Oncology: How Will it Affect Cancer Care?

Historically, patients with cancer largely have deferred to their physicians regarding treatment recommendations. Today, however, there are signals that the cost to patients is beginning to play a bigger role in their willingness to accept physician-recommended treatments. Kantar Health examines the advent of patient consumerism in cancer care and portends what pharmaceutical companies may be facing in the future as cost-shifting continues to evolve.

The OBR Top 10 Oncology Stories of 2011

Rounding out our January issue, we bring you the top 10 media stories of 2011. It’s been an exciting year in oncology as evidenced by several new treatment options receiving FDA approval, to lung cancer screening, to the revocation (by the FDA anyway) of the Avastin breast cancer indication.

The 4th Annual Outlook on the Pharmaceutical Promotional Landscape Within Oncology

As in previous years, ImpactRx and OBR have teamed up to bring you an annual year-end analysis of pharmaceutical/biotech sales representative detailing efforts in oncology. The research shows how oncologists perceive the various sales forces and promotional efforts. Plus, aren’t you a bit curious how effective those tablet computers are?

View the January issue of OBR green »